Clinical Trials Browser

Myeloid Malignancies × olutasidenib × Clear all

NCT06668584 2026-03-04

A Phase II Open-label Study of Olutasidenib Post-transplant Maintenance Therapy for Patients With IDH1-mutated Myeloid Malignancies

Phase 2 Recruiting

Myeloid Malignancies